Abstracts - Orals, Featured Poster Presentations, and Posters
SUN 554-573-Ovarian & Uterine Function I
Expo Halls ABC (Moscone Center)
Poster Board SUN-561
To determine the accuracy of self-report of smoking in infertile women with polycystic ovary syndrome (PCOS) desiring to conceive, and to assess the effects of treatment on smoking status
Nested case-control study.
Multi-center clinical trial at academic medical centers.
A total of 148 women divided into three groups: current smokers, past smokers and non-smokers
Measure serum cotinine levels during the first treatment cycle and a subsequent treatment cycle (Cycle 5).
MAIN OUTCOME MEASURE(S):
Self reported smoking, serum cotinine levels, biometric and hormonal parameters.
Overall self report of smoking agreed well with smoking status as determined by measure of serum cotinine levels, at 90% or better for each of the groups at baseline (98% of never smokers had cotinine levels < 15 ng/mL compared to 90% of past smokers, and 6% of current smokers). At baseline, total testosterone was higher in the current smokers compared to past smokers (P = 0.03) and never smokers (P = 0.02). In all 3 self reported groups, SHBG increased over time (P<.0001 for all), as did insulin and HOMA-IR in the current smokers (P=0.01 for both).There were minor changes in smoking status as determined by serum cotinine levels over time, with the greatest change found in the smoking groups (past or current smokers).
Self-report of smoking in infertile women with PCOS is accurate, with 10% of past smokers likely to have a current smoking history, and unlikely to change over time with treatment, though there is greater lability in subjects with a smoking history.
1. Triche EW, Hossain N. Environmental factors implicated in the causation of adverse pregnancy outcome. Semin Perinatol 2007;31:240-2. 2. Tomeo CA, Field AE, Berkey CS, Colditz GA, Frazier AL. Weight concerns, weight control behaviors, and smoking initiation. Pediatrics 1999;104:918-24. 3. Legro RS, Myers ER, Barnhart HX, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertility and sterility 2006;86:914-33. 4. Cupisti S, Haberle L, Dittrich R, et al. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. Fertility and sterility 2010;94:673-7. 5. Glintborg D, Mumm H, Hougaard DM, Ravn P, Andersen M. Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 white patients with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2012;28:170-4. 6. How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease: A Report of the Surgeon General. Rockville, MD: Public Health Service, Office of Surgeon General. In: Services UDoHaH, ed.; 2010. 7. Gorber SC, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2009;11:12-24. 8. Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. BMJ 2009;339:b4347. 9. Dietz PM, Homa D, England LJ, et al. Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States. American journal of epidemiology 2011;173:355-9. 10. Rosevear SK, Holt DW, Lee TD, Ford WC, Wardle PG, Hull MG. Smoking and decreased fertilisation rates in vitro. Lancet 1992;340:1195-6. 11. Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002;17:3220-3. 12. Pasch LA, Gregorich SE, Katz PK, et al. Psychological distress and in vitro fertilization outcome. Fertility and sterility 2012;98:459-64. 13. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. The New England journal of medicine 2007;356:551-66. 14. Biochemical verification of tobacco use and cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2002;4:149-59. 15. Hughes EG, Lamont DA, Beecroft ML, Wilson DM, Brennan BG, Rice SC. Randomized trial of a "stage-of-change" oriented smoking cessation intervention in infertile and pregnant women. Fertility and sterility 2000;74:498-503. 16. Wong SL, Malaison E, Hammond D, Leatherdale ST. Secondhand Smoke Exposure Among Canadians: Cotinine and Self-Report Measures From the Canadian Health Measures Survey 2007-2009. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2012. 17. Rausch ME, Legro RS, Barnhart HX, et al. Predictors of pregnancy in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism 2009;94:3458-66.
Disclosure: RSL: Research Funding, NICHD. GC: Research Funding, NICHD. ARK: Owner, Merck & Co.. WDS: Research Funding, NICHD. MPD: Research Funding, Abbott Laboratories, Research Funding, Ferring Pharmaceuticals, Research Funding, Boehringer Ingelheim, Research Funding, EMD Serono, Consultant, Genzyme, Consultant, Auxogyn, Consultant, Neomend, Research Funding, NICHD. CC: Research Funding, NICHD. MPS: Research Funding, NICHD. BRC: Speaker, Merck & Co., Committee Member, Seminars in Reproductive Medicine. PGM: Research Funding, NICHD. NAC: Research Funding, NICHD. GGG: , Cassat RRG, Research Funding, NICHD. JEN: Research Funding, NICHD. ERM: Research Funding, GSK Inc., Consultant, Merck & Co.. HZ: Research Funding, NICHD. JF: Consultant, Cypress Bioscience, Consultant, J&J, Consultant, GSK, Consultant, Pfizer, Inc., Research Funding, Pfizer, Inc., Advisory Group Member, Pfizer, Inc.. Nothing to Disclose: SAC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
Sources of Research Support:
This work was supported by NIH/NICHD grants U10 HD38998 (WS), U10 HD055925 (HZ), U10 HD39005 (MD), U10 HD27049 (CC), H10 HD055944 (PC), U10 HD055942 (RB), U10 HD055936 (GC), U10 HD38992 (RL), GCRC grant MO1RR10732 and construction grant C06 RR016499 to Pennsylvania State University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NICHD or NIH.